GGrantIndex
← Leaderboards

Infectious Disease Research Institute

Seattle, WA

Compare ↔
$13,316,270
Total funding
9
Grants

Funding mix

By agency

NIH$13,316,270 · 9

By mechanism

R01$9,142,666 · 7
UC1$4,095,564 · 1
R03$78,040 · 1

Investigators at Infectious Disease Research Institute

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

Not enough data

Emerging Leaders

6–10 yrs in

Not enough data

Largest grants

Development &Manufacture of an MDR Tuberculosis Vaccine$4,095,564
UC1 · FY2005 · AI
Leishmania Antigens Defined by Human Immune Responses$551,120
R01 · FY2005 · AI
Leishmania Antigens Defined by Human Immune Responses$536,093
R01 · FY2004 · AI
THE ROLE OF LYT1 PROTEIN IN TRYPANOSOMA CRUZI$446,041
R01 · FY2002 · AI
THE ROLE OF LYT1 PROTEIN IN TRYPANOSOMA CRUZI$441,437
R01 · FY2000 · AI
THE ROLE OF LYT1 PROTEIN IN TRYPANOSOMA CRUZI$433,051
R01 · FY2001 · AI
LEISHMANIA ANTIGENS DEFINED BY HUMAN IMMUNE RESPONSES$426,721
R01 · FY2000 · AI
Human T Cell Antigens of Mycobacterium tuberculosis$397,752
R01 · FY2005 · AI
The Function of NKT Cells During T Cruzi Infection$384,750
R01 · FY2002 · AI
The Function of NKT Cells During T Cruzi Infection$384,750
R01 · FY2003 · AI
The Function of NKT Cells During T Cruzi Infection$384,750
R01 · FY2004 · AI
HUMAN T CELLS ANTIGENS OF MYCOBACTERIUM TUBERCULOSIS$378,081
R01 · FY2003 · AI
HUMAN T CELLS ANTIGENS OF MYCOBACTERIUM TUBERCULOSIS$356,486
R01 · FY2001 · AI
HUMAN T CELLS ANTIGENS OF MYCOBACTERIUM TUBERCULOSIS$346,153
R01 · FY2000 · AI
T. cruzi-induced Protective and Pathologic CD4 Responses$342,000
R01 · FY2003 · AI
T. cruzi-induced Protective and Pathologic CD4 Responses$342,000
R01 · FY2002 · AI
T. cruzi-induced Protective and Pathologic CD4 Responses$342,000
R01 · FY2004 · AI
HUMAN T CELLS ANTIGENS OF MYCOBACTERIUM TUBERCULOSIS$332,888
R01 · FY2002 · AI
The Function of NKT Cells During T Cruzi Infection$304,835
R01 · FY2001 · AI
VACCINE DEVELOPMENT IN TUBERCULOSIS$293,446
R01 · FY2001 · AI